Date: 2011-03-03
Type of information: Grant
Company: Bioalliance Pharma and a consortium of laboratories and companies (France)
Investors: FUI (Fond Unique Interministériel - a French program supporting collaborative research projects)(France)
Amount: € 2 million including €743,000 specifically allocated to BioAlliance Pharma.
Funding type: grant
Planned used: This award of €2 million in funding over 30 months from the « Fond Unique Interministériel » (a French program supporting collaborative research projects) includes an amount of €743,000 specifically allocated to BioAlliance Pharma. The program aims at establishing the proof of concept for the administration by mucosal route of biological products. The first application is a peptide benefiting from the delivery properties of the Lauriad™ mucoadhesive technology. This program will also permit to test the Lauriad™ technology in the veterinary area. This collaborative program, co-labelled by both « Clusters of excellence » Medicen Paris Region and Atlanpôle, aims at designing a flu vaccine administered by mucosal route. The consortium is led by BioAlliance Pharma and involves several academic centers and industrial partners: Laboratoire de Virologie et Pathologies Humaines VirPath (Lyon), headed by Pr. Bruno Lina, National flu reference center, Laboratoire EA 401 Matériaux et Produits de Santé, headed by Pr. Pierre Tchoreloff from Paris XI University, specialized in optimization of peptide formulations, Sogeval, a French veterinary drug company, which develops, produces, and markets veterinary products, Gredeco, founded by Pr. Lofti Ben Slama (Paris), will be in charge of the studies on peptide mucous penetration. Pr Pierre Dellamonica’s team, from Nice University Hospital, worldwide known for its expertise in infectiology, will be in charge of immunological assessment prior to entry into clinical phase.
Others:
Therapeutic area: Infectious diseases
